ClinicalTrials.gg
RecruitingNCT05855018Updated May 11, 2023

A Study of Atropine Sulfate in Healthy Chinese Volunteers

A Phase 1 interventional study of Atropine sulfate eye drops in Pharmacokinetics, sponsored by Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Limited. Recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-11.

Sponsored by Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Limited (formerly part of Lee's Pharmaceutical Limited) · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by Jun 2023, 3 years 5 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

To evaluate the systemic pharmacokinetics and the safety of atropine sulfate eye drops in healthy volunteers.

Read the detailed description

This is a randomized, open-label, phase I clinical study evaluating the systemic pharmacokinetics and safety of atropine sulfate eye drops in healthy Chinese volunteers.Three concentrations will be investigated, each concentration group must contain both male and female subjects, and each subject receives only one concentration of atropine sulfate eye drop in this study.

The three treatment arms are:

Atropine sulfate dose A (low concentration)

Atropine sulfate dose B (medium concentration)

Atropine sulfate dose C (high concentration)

02

Conditions studied

  • Pharmacokinetics
03

In context

Lead sponsor

This is the only study on the registry with Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Limited as lead sponsor.

First submitted after Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Limited left Lee's Pharmaceutical Limited.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy subject is a male or female Chinese with his/her biological parents and grandparents are of Chinese ethnicity, aged 18-45 (including cut-off value) at screening;
  2. Subject with a (BMI) between 19.0-26.0kg/m2 (including cut-off value), male weight ≥50.0kg, female weight ≥45.0kg at screening and D0;
  3. Subject is in good health, as determined by the investigator, based on medical history, no findings of clinical significant abnormalities at physical examination, vital signs, and clinical laboratory tests at screening and D0;

Exclusion criteria

Exclusion Criteria:

  1. Subject with any eye with corrected visual acuity \<1.0, abnormal intraocular pressure, slit lamp and fundus examination.
  2. Subject with history of eye diseases, including the history of internal eye surgery or laser surgery.
  3. Subject with clinically significant history of the central nervous system, mental, cardiovascular, kidney, liver, respiratory, metabolic, and musculoskeletal system diseases etc., which may endanger the safety of the subject or affect the results of the study, as judged by the investigator.
  4. Subject with clinically significant history of allergies, such as drug allergies, especially those who are allergic to any component of atropine sulfate eye drops.
  5. On average, subject smokes more than 5 cigarettes per day or that who ex-smokes less than 3 months.
  6. Subject has used any topical or systemic antimuscarinic/anticholinergic drugs (e.g., atropine, 1-hyoscyamine, tropicamide, chlorpheniramine, diphenhydramine, oxytropine, cyclic antidepressants, etc.) within 3 weeks before screening.
  7. Subject has used any local or systemic drugs (including any prescription or over-the-counter drugs) within 2 weeks before screening.
  8. Subject has participated in interventional clinical trials within 3 months before screening.
  9. Subject who has worn contact lenses or cosmetic contact lenses within 1 weeks before screening.
  10. Subject who is pregnant or breastfeeding.
  11. The investigator believes that the subject is not suitable to participate in the trial.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Atropine sulfate Concentration A

    Subjects will be treated with atropine sulfate eye drop (at dosage Concentration A), administered once daily (QD).

    Drug: Atropine sulfate eye drops

  • Experimental
    Atropine sulfate Concentration B

    Subjects will be treated with atropine sulfate eye drop (at dosage Concentration B), administered once daily (QD).

    Drug: Atropine sulfate eye drops

  • Experimental
    Atropine sulfate Concentration C

    Subjects will be treated with atropine sulfate eye drop (at dosage Concentration C), administered once daily (QD).

    Drug: Atropine sulfate eye drops

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum concentration (Cmax)

    Measure the concentration of analyte in the blood to evaluate drug pharmacokinetics

    Time frame: From 1 hour before administration to 24 hours after administration

  2. Time of Cmax (Tmax)

    Measure the concentration of analyte in the blood to evaluate drug pharmacokinetics

    Time frame: From 1 hour before administration to 24 hours after administration

  3. Time of half-life (t1/2)

    Measure the concentration of analyte in the blood to evaluate drug pharmacokinetics

    Time frame: From 1 hour before administration to 24 hours after administration

  4. Area Under time-concentration Curve from 0 to last draw time (AUC0-t)

    Measure the concentration of analyte in the blood to evaluate drug pharmacokinetics

    Time frame: From 1 hour before administration to 24 hours after administration

  5. Area Under time-concentration Curve from 0 to infinity time (AUC(0-∞))

    Measure the concentration of analyte in the blood to evaluate drug pharmacokinetics

    Time frame: From 1 hour before administration to 24 hours after administration

  6. Minimum concentration (Cmin)

    Measure the concentration of analyte in the blood to evaluate drug pharmacokinetics

    Time frame: From 1 hour before administration to 24 hours after administration

  7. Volume of distribution (Vd)

    Measure the concentration of analyte in the blood to evaluate drug pharmacokinetics

    Time frame: From 1 hour before administration to 24 hours after administration

  8. Elimination rate constant (Kel)

    Measure the concentration of analyte in the blood to evaluate drug pharmacokinetics

    Time frame: From 1 hour before administration to 24 hours after administration

  9. Clearance (CL)

    Measure the concentration of analyte in the blood to evaluate drug pharmacokinetics

    Time frame: From 1 hour before administration to 24 hours after administration

  10. Apparent Clearance (CL/F)

    Measure the concentration of analyte in the blood to evaluate drug pharmacokinetics

    Time frame: From 1 hour before administration to 24 hours after administration

Secondary outcomes

  1. Slit-lamp eye examination results change from baseline to Day 7

    Evaluate the anterior segment of the eye, including the eyelids, cornea, conjunctiva, anterior chamber, iris and lens, and record abnormalities

    Time frame: on Day 0 and Day 7

  2. Fundoscopy eye examination results change from baseline to Day 7

    Evaluate the condition of the fundus, including the vitreous body, optic disc, macula, peripheral retina and retinal blood vessels

    Time frame: on Day 0 and Day 7

  3. Intraocular pressure change from baseline to Day 7

    Use non-contact tonometer to measure intraocular pressure

    Time frame: on Day 0 and Day 7

  4. Vision acuity change from baseline to Day 7

    Using Best-corrected LogMAR scale

    Time frame: on Day 0 and Day 7

  5. The mean change of pupil diameter from baseline to Day 7

    Use ophthalmic biometry equipment to measure pupil diameter

    Time frame: on Day 0 and Day 7

  6. The mean change of accommodation amplitude from baseline to Day 7

    Use a Phoropter to measure the accommodation amplitude using the negative lens method

    Time frame: on Day 0 and Day 7

07

Study locations

1 of 1 sites recruiting
  • HKU Eye Centre
    Hong Kong, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2023; primary completion for Jun 2023, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2023
First posted
May 11, 2023
StartEst.
May 9, 2023
Primary completionEst.
Jun 2023
CompletionEst.
Jun 2023
Last update
May 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05855018
Responsible party
Sponsor
First posted
May 11, 2023
Start date
May 9, 2023 (estimated)
Primary completion
Jun 2023 (estimated)
Completion
Jun 2023 (estimated)
Last update
May 11, 2023

Study contacts

Christopher LEUNG
Contact
cleung21@hku.hk
+852 25181430
Christopher LEUNG
principal investigator · HKU Eye Centre

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atropine

Start the discussion